- Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
[作者：Gerard, JP; Azria, D; Gourgou-Bourgade, S; Martel-Laffay, I; Hennequin, C; Etienne, PL; Vendrely, V; Francois, E; de La Roche, G; Bouche, O; Mirabel, X; Denis, B; Mineur, L; Berdah, JF; Mahe, MA; Becouarn, Y; Dupuis, O; Lledo, G; Montoto-Grillot, C; Conroy, T,期刊：Journal of clinical oncology, 页码：1638-1644 , 文章类型： Article，,卷期：2010年28-10]
- Purpose Neoadjuvant chemoradiotherapy is considered a standard approach for T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified radiotherapy plus capecit...
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
[作者：Colucci, G; Labianca, R; Di Costanzo, F; Gebbia, V; Carteni, G; Massidda, B; Dapretto, E; Manzione, L; Piazza, E; Sannicolo, M; Ciaparrone, M; Cavanna, L; Giuliani, F; Maiello, E; Testa, A; Pederzoli, P; Falconi, M; Gallo, C; Di Maio, M; Perrone, F,期刊：Journal of clinical oncology, 页码：1645-1651 , 文章类型： Article，,卷期：2010年28-10]
- Purpose Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil. The Gruppo Italiano Pancreas 1 randomized phase III tria...
- Y-90-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
[作者：Bushnell, DL; O'Dorisio, TM; O'Dorisio, MS; Menda, Y; Hicks, RJ; Van Cutsem, E; Baulieu, JL; Borson-Chazot, F; Anthony, L; Benson, A; Oberg, K; Grossman, AB; Connolly, M; Bouterfa, H; Li, Y; Kacena, KA; LaFrance, N; Pauwels, SA,期刊：Journal of clinical oncology, 页码：1652-1659 , 文章类型： Article，,卷期：2010年28-10]
- Purpose Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the dise...
- Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
[作者：Wong, VWS; Chan, SL; Mo, F; Chan, TC; Loong, HHF; Wong, GLH; Lui, YYN; Chan, ATC; Sung, JJY; Yeo, W; Chan, HLY; Mok, TSK,期刊：Journal of clinical oncology, 页码：1660-1665 , 文章类型： Article，,卷期：2010年28-10]
- Purpose Hepatitis B virus (HBV) infection is an important etiology for hepatocellular carcinoma (HCC). We aim to develop a simple clinical score in predicting the risk of HCC among HBV carriers. Patients and Methods We f...
- Prognostic Value of Changes in Health-Related Quality of Life Scores During Curative Treatment for Esophagogastric Cancer
[作者：Djarv, T; Metcalfe, C; Avery, KNL; Lagergren, P; Blazeby, JM,期刊：Journal of clinical oncology, 页码：1666-1670 , 文章类型： Article，,卷期：2010年28-10]
- Purpose Accumulating evidence suggests that health-related quality of life (HRQL) data before treatment predict survival, but the prognostic value of changes in HRQL scores after treatment is unknown. The aim of this stu...
- Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
[作者：Lo, SS; Mumby, PB; Norton, J; Rychlik, K; Smerage, J; Kash, J; Chew, HK; Gaynor, ER; Hayes, DF; Epstein, A; Albain, KS,期刊：Journal of clinical oncology, 页码：1671-1676 , 文章类型： Article，,卷期：2010年28-10]
- Purpose The 21-gene Recurrence Score (RS) assay has been validated to quantify the risk of distant recurrence in tamoxifen-treated patients with lymph node-negative, estrogen receptor-positive breast cancer and predict m...
- Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
[作者：Mamounas, EP; Tang, G; Fisher, B; Paik, S; Shak, S; Costantino, JP; Watson, D; Geyer, CE; Wickerham, DL; Wolmark, N,期刊：Journal of clinical oncology, 页码：1677-1683 , 文章类型： Article，,卷期：2010年28-10]
- Purpose The 21-gene OncotypeDX recurrence score (RS) assay quantifies the risk of distant recurrence in tamoxifen-treated patients with node-negative, estrogen receptor (ER)-positive breast cancer. We investigated the as...
- Breast Cancer Subtypes and the Risk of Local and Regional Relapse
[作者：Voduc, KD; Cheang, MCU; Tyldesley, S; Gelmon, K; Nielsen, TO; Kennecke, H,期刊：Journal of clinical oncology, 页码：1684-1691 , 文章类型： Article，,卷期：2010年28-10]
- Purpose The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer. Subtype assignment was accomplished using a validated s...
- Employment Among Survivors of Lung Cancer and Colorectal Cancer
[作者：Earle, CC; Chretien, Y; Morris, C; Ayanian, JZ; Keating, NL; Polgreen, LA; Wallace, R; Ganz, PA; Weeks, JC,期刊：Journal of clinical oncology, 页码：1700-1705 , 文章类型： Article，,卷期：2010年28-10]
- Purpose To identify the frequency of and factors associated with changes in employment among cancer survivors. Methods This prospective cohort study took place in the context of the population-based Cancer Care Outcomes ...
- TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis
[作者：Feldman, DR; Sheinfeld, J; Bajorin, DF; Fischer, P; Turkula, S; Ishill, N; Patil, S; Bains, M; Reich, LM; Bosl, GJ; Motzer, RJ,期刊：Journal of clinical oncology, 页码：1706-1713 , 文章类型： Article，,卷期：2010年28-10]
- Purpose We previously reported a dose-finding and phase II trial of the TI-CE regimen (paclitaxel [T] plus ifosfamide [I] followed by high-dose carboplatin [C] plus etoposide [E] with stem-cell support) in germ cell tumo...
- Risk Factors for Prostate Cancer Detection After a Negative Biopsy: A Novel Multivariable Longitudinal Approach
[作者：Gann, PH; Fought, A; Deaton, R; Catalona, WJ; Vonesh, E,期刊：Journal of clinical oncology, 页码：1714-1720 , 文章类型： Article，,卷期：2010年28-10]
- Purpose To introduce a novel approach for the time-dependent quantification of risk factors for prostate cancer (PCa) detection after an initial negative biopsy. Patients and Methods Data for 1,871 men with initial negat...
|